Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Interview With Siddhartha Mukherjee, Author of The Emperor of All Maladies

March 4th 2011

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

Tasigna Moves to the Front-Line in CML

March 4th 2011

The FDA approved Tasigna (nilotinib) as a first-line treatment for patients with newly diagnosed Philadelphia- chromosome positive (Ph ) chronic myeloid leukemia (CML), the first new drug approved for this indication in nearly a decade.

Therapy Class Review: Blood Modifiers

March 2nd 2011

In reviewing the therapeutic category of blood modifiers, there are 3 areas of focus

Comorbid Diabetes Increases Risk of Listeria

March 2nd 2011

Patients with cancer and comorbid type 2 diabetes have 5 times the risk of contracting listeria, a rare bacterial illness caused by eating contaminated food.

Flash Findings: Cancer Facts: August 12, 2010

August 12th 2010

A collection of cancer statistics and facts

Five-year Follow-Up of 300 Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy of CLL

July 8th 2010

Final results for the complete cohort of 300 patients with chronic lymphocytic leukemia (CLL) receiving the FCR (fludarabine, cyclophosphamide, and rituximab)regimen were presented at this year%u2019s American Society of Clinical Oncology meeting.

Bio-Buzz: Advances in the Treatment of Multiple Myeloma

July 6th 2010

Treatment advances focus on the potential use of Bortezomib and Lenalidomide in the front-line setting to improve patients' response rates.

Stanford Researchers Lock on to Novel Leukemia Treatment Target

May 24th 2010

Stanford University School of Medicine investigators may have discovered a new chemotherapy target for a deadly form of leukemia. A molecular signal, glycogen synthase kinase 3 (GSK3), known to regulate cell growth appears to play a %u201Cdouble agent%u201D role.

50th Annual Meeting of the American Society of Hematology

January 27th 2009

Highlights from the 50th Annual Meeting of the American Society of Hematology.